SOURCE: Fresenius Medical Care

Fresenius Medical Care

October 22, 2015 01:04 ET

Fresenius Medical Care Sets Clinical Standards in Singapore

SINGAPORE--(Marketwired - Oct 22, 2015) - Fresenius Medical Care the - THE RENAL COMPANY is the world's leading provider of dialysis products and services has set new clinical standards in Singapore.

As of June 2015, its three clinics, Fresenius Medical Care Napier Dialysis Clinic, Fresenius Medical Care Tanglin Dialysis Clinic and ARC Mount Elizabeth Dialysis Clinic, became the first private dialysis clinics in Singapore to achieve international accreditation by the Australian Council on Healthcare Standards International (ACHSI). The accreditation is a public recognition of the achievement of accreditation, demonstrated through an independent external peer review assessment of that organisation's level of performance in relation to specific standards. It was accomplished in recognition of the achievement of the 'Evaluation and Quality Improvement Program' (EQuIP) for day procedure centres standards and a commitment to continuous improvement in the quality of care, service and safety.

In a ceremony held to celebrate this advancement, Dr. Desmond Yen, Executive Director of ACHSI, presented the signed accreditation certificate to Anthony Tann, Managing Director, Fresenius Medical Care Singapore. Tann stated, "This is a great moment for all of us, as well as for Singapore. It was a very rewarding learning journey for the different teams contributing to this important project. We will continue driving quality care standards for patients in Singapore and beyond while striving for further clinic accreditations under ACHSI."

Excellent renal care is of critical importance for Singapore. The country is the 4th highest ranked for ESRD (end-stage renal disease) incidence world-wide1 with 65 percent of chronic kidney disease caused by diabetes2. The Renal Registry's interim report for 1999-2014 indicates that close to a total of 6,000 patients were already receiving dialysis treatment at the end of last year3.

Thanks to the constant commitment of Fresenius Medical Care's staff, the clinics guarantee high quality operations and patient safety. With their accreditation status, the three Fresenius Medical Care clinics will serve as a model to enhance the country's development in fulfilling safety and care standards and ultimately optimising patient outcomes.

ACHSI (Australian Council on Healthcare Standards International) is the leading healthcare accreditation body in Australia and has developed an international reputation providing accreditation in many countries.

1Saran R, Li Y, Robinson B, et al. US Renal Data System 2014 annual data report: epidemiology of kidney disease in the
 United States. Am J Kidney Dis. 2015; Fig10.1, 66(1) (suppl 1):S1-S306.
2 Singapore Renal Registry Annual Registry Report 1999 - 2014 (INTERIM) Figure 1.4; 2014; p7
3 Singapore Renal Registry Annual Registry Report 1999 - 2014 (INTERIM) Table 2.1; 2014; p8

Dr Desmond Yen, Executive Director of ACHSI (third from right, back row) with the Fresenius Medical Care Singapore management and clinical team during the accreditation ceremony.

Company logo

About Fresenius Medical Care
Fresenius Medical Care is the world's largest provider of products and services for individuals with renal diseases of which more than 2.6 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,421 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 289,610 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with the core business, the company focuses on expanding the range of additional medical services in the field of care coordination.

For more information about Fresenius Medical Care, visit the company's website at

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

Contact Information

  • Media Contact:
    Dr. Alexandra Villar
    Director Marketing Communications South Asia Pacific
    Fresenius Medical Care
    Email Contact